Core Insights - Pulmovant has completed enrollment in the Phase 2 PHocus clinical trial for mosliciguat, targeting pulmonary hypertension associated with interstitial lung disease (PH-ILD) [1][2][3] - Mosliciguat is a potential first-in-class, once-daily inhaled sGC activator designed to provide targeted pulmonary vasodilation with limited systemic side effects [2][5] - The PHocus trial enrolled approximately 120 adult participants and is expected to report topline data in the second half of 2026 [2][3][6] Company Overview - Pulmovant is a clinical-stage biotechnology company focused on transforming the lives of patients with pulmonary diseases and is a subsidiary of Roivant [1][6] - The company aims to address significant unmet medical needs in patients suffering from PH-ILD, a condition with limited treatment options [3][4] - The rapid enrollment pace of the PHocus trial, completed in under 12 months, highlights the strong demand for new therapeutic options in this area [2][3][6] Product Details - Mosliciguat targets the sGC enzyme in the nitric oxide/cGMP signaling pathway, promoting vasodilation and potentially offering broad applications across pulmonary hypertension [5][7] - In the Phase 1b ATMOS study, inhaled mosliciguat demonstrated a mean peak reduction in pulmonary vascular resistance (PVR) of up to 38%, indicating its potential efficacy [5]